A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer — Stella
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations(64 sites)
United States
American Institute of Research, Los Angeles, California
USC Kenneth Norris Jr Cancer Hospital, Los Angeles, California
University of California, Irvine, Orange, California
Genesis Research, LLC - San Diego, San Diego, California
Advent Health, Denver, Colorado
Colorado Urology - St. Anthony Hospital Campus, Lakewood, Colorado
Yale School of Medicine, New Haven, Connecticut
Medstar Georgetown University Hospital, Washington D.C., District of Columbia
Sarasota Memorial Healthcare System, Sarasota, Florida
Emory University, Atlanta, Georgia
Georgia Urology, Atlanta, Georgia
Boise VA Medical Center, Boise, Idaho
NextStage Clinical Research, Lisle, Illinois
Indiana University, Indianapolis, Indiana
Wichita Urology Group, Wichita, Kansas
Anne Arundel Urology, PA, Annapolis, Maryland
Chesapeake Urology Research Associates, Hanover, Maryland
Atlantic Health, Morristown, New Jersey
Roswell Park Cancer Institute, Buffalo, New York
Great Lakes Physician PC d/b/a Western new York Urology Associates, Cheektowaga, New York
Northwell Health -The Arthur Smith Institute for Urology, Lake Success, New York
James J. Peters VA Medical Center, The Bronx, New York